Navigation Links
Transcept Pharmaceuticals to Present at BIO Investor Forum
Date:9/29/2010

Transcept Pharmaceuticals to Present at BIO Investor Forum -- POINT RICHMOND, Calif., Sept. 29 /PRNewswire/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Health Care & Hospitals, Medical Pharmaceuticals, Pharmaceuticals, Trade Show News Click to view news release full screen  

Transcept Pharmaceuticals to Present at BIO Investor Forum

 

POINT RICHMOND, Calif., Sept. 29 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, today announced that Transcept management is scheduled to present a general business overview at the BIO Investor Forum in San Francisco on October 6, 2010 at 3:00 p.m. PDT.

A live audio webcast and replay of this presentation may be accessed at http://www.veracast.com/webcasts/bio/investorforum2010/37216438.cfm and on the Transcept Investor webpage at www.transcept.com.

About TransceptTranscept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. The most advanced Transcept product candidate is Intermezzo® (zolpidem tartrate sublingual tablet), for which a New Drug Application (NDA) was submitted to the U.S. Food and Drug Administration (FDA) in September 2008 seeking approval as a prescription sleep aid for use in the middle of the night at the time a patient awakens and has difficulty returning to sleep. In October 2009, Transcept received a Complete Response Letter from the FDA on the Intermezzo® NDA and is working to respond to issues raised in the letter. Transcept and Purdue Pharmaceutical Products L.P. have entered into a collaboration agreement for the development and commercialization of Intermezzo® in the United States.  Transcept is also developing TO-2061, an ultra low dose ondansetron augmentation therapy for patients with obsessive compulsive disorder (OCD) who have not adequately responded to treatment with SSRIs.  Transcept plans to begin a Phase 2 study of TO-2061 in 2011.  For further information, please visit the Transcept website at: www.transcept.com.

Forward Looking Statements This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release are forward-looking statements. An example of such a statement is our plan to begin a Phase 2, double-blind, placebo-controlled study of TO-2061 in 2011. Transcept may not actually carryout this plan. Various important factors could cause actual events to differ materially from the forward-looking statements that Transcept makes, include the outcomes from planned Phase 1 studies of TO-2061 and discussions with the FDA about our plan to move forward with the Phase 2 study; dependence on third parties to manufacture TO-2061 and carry-out the planned study; our success in efforts to seek approval for Intermezzo®, our lead product candidate, and the business of Transcept generally. These and other risks are described in greater detail in the "Risk Factors" section of Transcept periodic reports filed with the SEC. Forward-looking statements do not reflect the potential impact of any future in-licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments Transcept may enter into or make. Transcept does not assume any obligation to update any forward-looking statements, except as required by law. Contact:Transcept Pharmaceuticals, Inc.Greg MannDirector, Corporate Communications(510) 215-3567gmann@transcept.com
'/>"/>

SOURCE Transcept Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Transcept Pharmaceuticals to Present at UBS Global Life Sciences Conference
2. Transcept Pharmaceuticals to Present at Rodman & Renshaw and Stifel Nicolaus Investor Conferences in September 2010
3. Transcept Pharmaceuticals Receives Notice of Allowance for Second U.S. Patent Application Covering Intermezzo(R)
4. Transcept Pharmaceuticals Scheduled to Meet With FDA to Discuss Intermezzo(R) Complete Response Letter
5. Transcept Pharmaceuticals Reports Third Quarter 2009 Financial Results
6. Transcept Pharmaceuticals to Present at Lazard Capital Markets Healthcare Conference on November 17
7. Transcept Pharmaceuticals to Report Third Quarter 2009 Results and Host Conference Call on November 12
8. Transcept Pharmaceuticals Receives Complete Response Letter from FDA on Intermezzo(R) New Drug Application
9. Transcept Pharmaceuticals to Report First Quarter 2009 Results
10. Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings
11. Transcept Pharmaceuticals Announces Intent to Submit New Drug Application for Intermezzo(R) in Third Quarter 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... , Jan. 17, 2017  Jazz Pharmaceuticals plc (Nasdaq: ... has been enrolled in a Phase 3 clinical trial ... supportive care (BSC) in the prevention of hepatic veno-occlusive ... stem cell transplant (HSCT) who are at high risk ... defibrotide clinical trial will be conducted across approximately 100 ...
(Date:1/17/2017)... According to a new market research report "Neural Network Software ... Vertical, and Region - Global Forecast to 2021" published by MarketsandMarkets, the market ... 2021, at a Compound Annual Growth Rate (CAGR) of 33.2%. ... ... Logo ...
(Date:1/17/2017)... -- OrthoAccel ® Technologies, Inc. announces that the ... Effect of Vibration on Molar Distalization," a study that ... Jay Bowman , this prospective, peer-reviewed clinical study concluded ... ® speeds up molar distalization rates in the ... days to move the upper molars into a normal, ...
Breaking Medicine Technology:
(Date:1/17/2017)... ... January 17, 2017 , ... In the crowded ... is a stand-out company for several differences from other mainstream brands. , ... demand, this is called 'Agile' manufacturing - http://www.leanproduction.com/agile-manufacturing.html . It allows them ...
(Date:1/17/2017)... ... , ... Kevin Harrington (one of the original Sharks from mega-hit reality series ... topic of Beauty and Personal Care. , Everyone makes New Year’s ... commit to these changes than beginning with personal care and beauty products? AsSeenOnTV.pro will ...
(Date:1/17/2017)... ... January 17, 2017 , ... Medic-CE , a ... firefighting professionals, has released four new continuing education courses as part of its ... in an online classroom and meet the requirements of the National Continued Competency ...
(Date:1/17/2017)... NJ (PRWEB) , ... January 17, 2017 , ... Neil ... and financial planning assistance to communities throughout the region, is launching a charity drive ... Heart disease is by far the deadliest killer in America, and is responsible for ...
(Date:1/17/2017)... ... January 17, 2017 , ... ... survivor Sandra Lee as keynote speaker for the 34th Annual Miami Breast Cancer ... making the announcement, PER® president, Phil Talamo, said, “We are delighted to have ...
Breaking Medicine News(10 mins):